Allianz Asset Management
VYGR icon

Allianz Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Allianz Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-38,602
Closed -$353K – 2564
2020
Q1 		$353K Sell
38,602
-218
-0.6% -$2.5K ﹤0.01% 2182
2019
Q4 		$542K Buy
38,820
+172
+0.4% +$2.5K ﹤0.01% 2408
2019
Q3 		$665K Sell
38,648
-55,300
-59% -$1.16M ﹤0.01% 2275
2019
Q2 		$2.05M Buy
93,948
+13,339
+17% +$305K ﹤0.01% 1873
2019
Q1 		$1.54M Sell
80,609
-834
-1% -$10.9K ﹤0.01% 1932
2018
Q4 		$766K Sell
81,443
-3,107
-4% -$39.9K ﹤0.01% 2133
2018
Q3 		$1.6M Buy
84,550
+15,102
+22% +$290K ﹤0.01% 2039
2018
Q2 		$1.36M Buy
+69,448
New +$1.37M ﹤0.01% 2109

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Allianz Asset Management's VYGR Position: Q2 2020 in Review

Allianz Asset Management sold out of Voyager Therapeutics (VYGR) in Q2 2020, closing a stake of 38,602 shares — an estimated $353K sold.

Allianz Asset Management first reported a position in VYGR in Q2 2018 and held it in 8 quarters. The position peaked at $2.05M in Q2 2019. 113 funds tracked by Wall St. Rank hold VYGR as of Q2 2020.

  • Allianz Asset Management reported no remaining Voyager Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Allianz Asset Management sold 38,602 Voyager Therapeutics shares in Q2 2020, an estimated $353K.
  • Allianz Asset Management first reported a position in Voyager Therapeutics in Q2 2018 and held it in 8 quarters.
  • Allianz Asset Management's Voyager Therapeutics position peaked at $2.05M in Q2 2019.
  • 113 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2020.

Based on Allianz Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.